Ardelyx (ARDX) Total Liabilities (2013 - 2026)
Ardelyx posted quarterly Total Liabilities of $355.9 million for Q1 2026, up 34.54% year-on-year from $264.5 million in Q1 2025, and up 6.34% on a QoQ basis from $334.7 million in Q4 2025.
Ardelyx (ARDX) has 14 years of Total Liabilities data on file, last reported at $355.9 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 34.54% year-over-year to $355.9 million; the trailing twelve-month figure through Mar 2026 stood at $355.9 million (up 34.54% YoY), and the FY2025 full-year result was $334.7 million, up 27.5% from the prior year.
- Total Liabilities for Q1 2026 stood at $355.9 million, up from $334.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $355.9 million in Q1 2026 and bottomed at $65.2 million in Q1 2022.
- The 5-year median for Total Liabilities is $191.5 million (2024), against an average of $188.0 million.
- The widest annual swing landed in 2022, when Total Liabilities retreated 17.95%; it then soared 123.19% in 2024.
- A 5-year view of Total Liabilities shows it stood at $91.7 million in 2022, then jumped by 42.54% to $130.8 million in 2023, then jumped by 100.72% to $262.5 million in 2024, then advanced by 27.5% to $334.7 million in 2025, then rose by 6.34% to $355.9 million in 2026.
- The last three Total Liabilities figures came in at $355.9 million (Q1 2026), $334.7 million (Q4 2025), and $331.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn | 355.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355.89 Mn |
| Dec 31, 2025 | 334.66 Mn |
| Sep 30, 2025 | 331.89 Mn |
| Jun 30, 2025 | 327.24 Mn |
| Mar 31, 2025 | 264.52 Mn |
| Dec 31, 2024 | 262.47 Mn |
| Sep 30, 2024 | 209.57 Mn |
| Jun 30, 2024 | 196.50 Mn |
| Mar 31, 2024 | 191.49 Mn |
| Dec 31, 2023 | 130.76 Mn |
| Sep 30, 2023 | 98.22 Mn |
| Jun 30, 2023 | 88.04 Mn |
| Mar 31, 2023 | 91.60 Mn |
| Dec 31, 2022 | 91.74 Mn |
| Sep 30, 2022 | 77.81 Mn |
| Jun 30, 2022 | 78.57 Mn |
| Mar 31, 2022 | 65.22 Mn |
| Dec 31, 2021 | 67.30 Mn |
| Sep 30, 2021 | 89.42 Mn |
| Jun 30, 2021 | 87.41 Mn |
| Mar 31, 2021 | 79.48 Mn |
| Dec 31, 2020 | 75.45 Mn |
| Sep 30, 2020 | 67.22 Mn |
| Jun 30, 2020 | 70.99 Mn |
| Mar 31, 2020 | 67.57 Mn |
| Dec 31, 2019 | 73.13 Mn |
| Sep 30, 2019 | 70.25 Mn |
| Jun 30, 2019 | 69.36 Mn |
| Mar 31, 2019 | 74.29 Mn |
| Dec 31, 2018 | 67.52 Mn |
| Sep 30, 2018 | 65.22 Mn |
| Jun 30, 2018 | 65.12 Mn |
| Mar 31, 2018 | 13.86 Mn |
| Dec 31, 2017 | 18.59 Mn |
| Sep 30, 2017 | 16.47 Mn |
| Jun 30, 2017 | 19.14 Mn |
| Mar 31, 2017 | 20.08 Mn |
| Dec 31, 2016 | 19.98 Mn |
| Sep 30, 2016 | 18.42 Mn |
| Jun 30, 2016 | 14.77 Mn |
| Mar 31, 2016 | 12.75 Mn |
| Dec 31, 2015 | 8.05 Mn |
| Sep 30, 2015 | 12.94 Mn |
| Jun 30, 2015 | 5.93 Mn |
| Mar 31, 2015 | 47.40 Mn |
| Dec 31, 2014 | 52.73 Mn |
| Sep 30, 2014 | 54.43 Mn |
| Jun 30, 2014 | 60.61 Mn |
| Dec 31, 2013 | 50.23 Mn |